Compare CULP & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | ATOS |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 36.2M |
| IPO Year | 1994 | 2010 |
| Metric | CULP | ATOS |
|---|---|---|
| Price | $3.04 | $5.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 27.7K | ★ 44.3K |
| Earning Date | 03-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,237,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $0.53 |
| 52 Week High | $4.75 | $7.56 |
| Indicator | CULP | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 45.35 |
| Support Level | $2.71 | $4.63 |
| Resistance Level | $3.13 | $5.12 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 10.98 | 32.38 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.